A comprehensive view of Valneva SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer and Valneva conclude enrollment for a Phase 3 trial of their Lyme disease vaccine, after delaying the trial since February; the firms hope to collect study data by 2025
Published: December 06, 2023 by BioPharma Dive
Pfizer and Valneva announce positive immunogenicity and safety data for their Lyme disease vaccine, VLA15, in children, adolescents, and adults, with the vaccine well-tolerated across all age groups
Published: September 07, 2023 by States News Service
Rutgers University begins late-stage pediatric clinical trials for Pfizer and Valneva's VLA15 Lyme disease vaccine; the vaccine targets the outer surface protein of the bacteria that causes Lyme disease
Published: May 23, 2023 by Record, The (Bergen County, NJ)
Pfizer, Valneva delay VLA 15 Lyme disease vaccine filing by a year after clinical trial issues; Pfizer to submit BLA to the FDA and EU for approval in 2026
Published: May 04, 2023 by FierceBiotech

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count